Candriam S.C.A. lessened its position in shares of Verona Pharma plc (NASDAQ:VRNA - Free Report) by 43.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 440,313 shares of the company's stock after selling 332,684 shares during the period. Candriam S.C.A. owned about 0.55% of Verona Pharma worth $20,448,000 at the end of the most recent reporting period.
A number of other large investors have also recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its holdings in shares of Verona Pharma by 20.7% in the fourth quarter. GAMMA Investing LLC now owns 1,612 shares of the company's stock valued at $75,000 after purchasing an additional 276 shares during the last quarter. Diversify Advisory Services LLC boosted its stake in shares of Verona Pharma by 5.2% during the 4th quarter. Diversify Advisory Services LLC now owns 6,166 shares of the company's stock worth $279,000 after buying an additional 305 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in shares of Verona Pharma by 8.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 22,848 shares of the company's stock valued at $1,061,000 after acquiring an additional 1,807 shares in the last quarter. EMC Capital Management grew its holdings in shares of Verona Pharma by 3,400.0% in the 4th quarter. EMC Capital Management now owns 3,500 shares of the company's stock valued at $163,000 after acquiring an additional 3,400 shares in the last quarter. Finally, Wrapmanager Inc. bought a new stake in Verona Pharma during the fourth quarter worth about $207,000. Institutional investors own 85.88% of the company's stock.
Verona Pharma Price Performance
NASDAQ VRNA traded down $3.30 during trading on Monday, hitting $61.35. 1,632,056 shares of the company's stock were exchanged, compared to its average volume of 1,552,571. The company has a current ratio of 13.03, a quick ratio of 12.88 and a debt-to-equity ratio of 0.93. The company has a market cap of $4.96 billion, a PE ratio of -31.95 and a beta of 0.39. Verona Pharma plc has a fifty-two week low of $11.39 and a fifty-two week high of $70.40. The stock's 50 day moving average price is $57.11 and its two-hundred day moving average price is $42.53.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Roth Capital set a $83.00 price target on Verona Pharma in a research note on Friday, February 28th. Truist Financial restated a "buy" rating and set a $57.00 target price (up from $44.00) on shares of Verona Pharma in a report on Wednesday, January 8th. HC Wainwright increased their price target on shares of Verona Pharma from $60.00 to $75.00 and gave the company a "buy" rating in a research note on Friday, February 28th. Wells Fargo & Company raised their target price on shares of Verona Pharma from $74.00 to $93.00 and gave the company an "overweight" rating in a research note on Friday, February 28th. Finally, Canaccord Genuity Group lifted their price objective on shares of Verona Pharma from $44.00 to $72.00 and gave the stock a "buy" rating in a research report on Wednesday, February 12th. Six equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $69.14.
Get Our Latest Stock Report on Verona Pharma
About Verona Pharma
(
Free Report)
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading
Before you consider Verona Pharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Verona Pharma wasn't on the list.
While Verona Pharma currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for March 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
